Galecto Inc
NASDAQ:GLTO
Galecto Inc
Research & Development
Galecto Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Galecto Inc
NASDAQ:GLTO
|
Research & Development
-$6.4m
|
CAGR 3-Years
45%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Research & Development
-kr1.5B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-37%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Research & Development
-kr1.6B
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-23%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Research & Development
-€292.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-22%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Research & Development
-kr802.1m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-6%
|
|
|
Saniona AB
STO:SANION
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Galecto Inc
Glance View
Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. The firm is focused on developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. The Company’s initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). The firm is developing GB0139 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Company’s product candidate portfolio also includes GB1211, a selective oral galectin-three inhibitor, which is being developed for the treatment of fibrosis related to non-alcoholic steatohepatitis (NASH), and GB2064, a selective oral inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which fibrosis reduces the ability to form blood cells.
See Also
What is Galecto Inc's Research & Development?
Research & Development
-6.4m
USD
Based on the financial report for Dec 31, 2024, Galecto Inc's Research & Development amounts to -6.4m USD.
What is Galecto Inc's Research & Development growth rate?
Research & Development CAGR 5Y
20%
Over the last year, the Research & Development growth was 73%. The average annual Research & Development growth rates for Galecto Inc have been 45% over the past three years , 20% over the past five years .
